Respiratory syncytial virus (RSV) is causing a high number of hospitalizations and deaths among children under 5, with infants under 1 year old being the most affected. The demand for drugs to treat RSV is surpassing the National Supply, creating a shortage. Dr. Céline Gounder, an epidemiologist and senior fellow at KFF, discusses the consequences of this drug shortage in treating RSV.

The post High demand for new RSV treatment for kids Outpaces National Supply appeared first on Balanced News Summary.